BET-PSMA-121
Showing 1 - 25 of 571
Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC Trial in Glen Burnie (177Lu-rhPSMA-10.1 injection,
Recruiting
- Prostate Cancer
- +5 more
- 177Lu-rhPSMA-10.1 injection
- 18F-rhPSMA-7.3 injection
-
Glen Burnie, Maryland
- +3 more
Feb 2, 2023
Prostate Cancer Trial (Darolutamide Oral Tablet [Nubeqa])
Not yet recruiting
- Prostate Cancer
- Darolutamide Oral Tablet [Nubeqa]
- (no location specified)
Jun 2, 2023
Metastatic Breast Cancer Trial in Herlev, Vejle (PARP inhibitor 2X-121)
Active, not recruiting
- Metastatic Breast Cancer
- PARP inhibitor 2X-121
-
Herlev, Denmark
- +1 more
Feb 1, 2023
Prostate Cancer Trial in Beijing (Al18F-PSMA-617, 68Ga-PSMA-617)
Recruiting
- Prostate Cancer
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
May 2, 2023
Prostatic Tumors, Castration-Resistant Trial in Darlinghurst, Pretoria (225^Ac-PSMA-617, 68^Ga-PSMA-11)
Recruiting
- Prostatic Neoplasms, Castration-Resistant
- 225^Ac-PSMA-617
- 68^Ga-PSMA-11
-
Darlinghurst, Australia
- +1 more
Nov 23, 2022
Eustachian Tube Dysfunction Trial (Balloon Eustachian Tuboplasty (BET) under general anesthesia., Insertion of catheter for
Not yet recruiting
- Eustachian Tube Dysfunction
- Balloon Eustachian Tuboplasty (BET) under general anesthesia.
- Insertion of catheter for probing and flushing the Eustachian tube under general anesthesia
- (no location specified)
Aug 9, 2023
TNBC - Triple-Negative Breast Cancer Trial in Brussels (Ga-PSMA PET/CT)
Recruiting
- TNBC - Triple-Negative Breast Cancer
- Ga-PSMA PET/CT
-
Brussels, BelgiumInstitut Jules Bordet
Sep 26, 2023
Prostatic Tumors, Castration-Resistant Trial in Rotterdam (Radionuclide Therapy)
Recruiting
- Prostatic Neoplasms, Castration-Resistant
- Radionuclide Therapy
-
Rotterdam, Zuid-Holland, NetherlandsErasmus Medical Center
Jun 5, 2023
Malignant Brain Tumors Trial in Berkel en Rodenrijs (procedure, device, other)
Recruiting
- Malignant Brain Tumors
- intra-arterial injection
- +2 more
-
Berkel en Rodenrijs, Zuid Holland, NetherlandsLaurens Groenendijk
Apr 3, 2023
Mucopolysaccharidosis Type II (MPS II) Trial in Brazil, United States (RGX-121)
Recruiting
- Mucopolysaccharidosis Type II (MPS II)
- RGX-121
-
Oakland, California
- +4 more
Dec 22, 2022
Advanced and/or Metastatic Solid Tumours Trial in Groningen (Radiolabelled CB307, CB307)
Recruiting
- Advanced and/or Metastatic Solid Tumours
- Radiolabelled CB307
- CB307
-
Groningen, NetherlandsUniversity Medical Center Groningen,
Apr 28, 2023
Cancer Trial in Meldola, Cesena ([177Lu]Lu-PSMA I&T)
Not yet recruiting
- Cancer
- [177Lu]Lu-PSMA I&T
-
Meldola, Forlì, Italy
- +1 more
May 10, 2023
Prostate Cancer, Localized Prostate Carcinoma Trial (PSMA-1007 Positron Emission Tomography (PET) scan)
Not yet recruiting
- Prostate Cancer
- Localized Prostate Carcinoma
- PSMA-1007 Positron Emission Tomography (PET) scan
- (no location specified)
Aug 14, 2023
PSMA-PET Imaging of Salivary Gland Tumours and Other Rare
Recruiting
- Salivary Gland Tumor
- Rare Malignant Neoplasm
- 68-Ga PSMA PET scan
-
Singapore, SingaporeNational Cancer Centre Singapore
Oct 11, 2022
Prostate Cancer Trial in Sapporo city, Kanazawa-city (177Lu-PSMA-617, 68Ga-PSMA-11, Best supportive/best standard of care)
Recruiting
- Prostate Cancer
- 177Lu-PSMA-617
- +2 more
-
Kashiwa, Chiba, Japan
- +6 more
Jan 23, 2023
Metastatic Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8 Trial (drug,
Not yet recruiting
- Metastatic Colorectal Adenocarcinoma
- +2 more
- BET Bromodomain Inhibitor ZEN-3694
- +6 more
- (no location specified)
Oct 25, 2023
Cystic Fibrosis Trial in Worldwide (VX-121/TEZ/D-IVA, ELX/TEZ/IVA, IVA)
Active, not recruiting
- Cystic Fibrosis
- VX-121/TEZ/D-IVA
- +5 more
-
Birmingham, Alabama
- +169 more
Dec 22, 2022
Prostate-Specific Membrane Antigen (PSMA) Radionuclide Therapy
Recruiting
- PSMA-positive Metastatic Castration-resistant Prostate Cancer Treated With PSMA Radionuclide Therapy
- PSMA radionuclide therapy
-
Dallas, TexasMethodist Dallas Medical Center
Aug 9, 2023